|
|
|
| Clinical study of Gastrodin combined with Oxiracetam in the treatment of cognitive impairment in elderly patients with ischemic stroke |
| LIANG Weiwei LIU Hua LI Xiaobo |
| Department of Geriatrics, the First People′s Hospital of Yunnan Province, Yunnan Province, Kunming 650031, China |
|
|
|
Abstract Objective To investigate clinical effect of Gastrodin combined with Oxiracetam in the treatment of cognitive impairment after ischemic stroke in the elderly. Methods One hundred and two elderly patients with cognitive impairment after ischemic stroke who were admitted to the First People′s Hospital of Yunnan Province from January 2016 to December 2018 were selected, they were divided into control group (n = 51, Oxiracetam treatment) and study group (n = 51, Gastrodin combined with Oxiracetam treatment) according to the random number table method, two groups were treated for 1 month. Clinical efficacy, adverse reactions, Montreal cognitive assessment scale (MoCA) score, activities of daily living (ADL) score and serum levels of neuron-specific enolase (NSE), homocysteine (Hcy) and high-sensitivity C-reactive protein (hs-CRP) were compared between two groups. Results The total clinical effective rate of study group was higher than that of control group (P < 0.05). After treatment, the scores of MoCA and ADL in two groups were higher than those before treatment, and the scores in study group were higher than those in control group (P < 0.05). After treatment, the levels of NSE, Hcy and hs CRP in two groups were lower than those before treatment, and the level in study group was lower than that in control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Gastrodin combined with Oxiracetam can effectively improve cognitive impairment in elderly patients with ischemic stroke. The safety of the drug is good and the effect is exact. The specific mechanism may be related to the down-regulation of NSE, Hcy, hs-CRP and other factors.
|
|
|
|
|
|
[1] Güler S，Naku?鬤 E，Utku U. Risk factors for ischemic stroke and stroke subtypes in patients with chronic kidney disease [J]. Ideggyogy Sz，2019，72（11/12）：389-396.
[2] 尹明宇，罗婧，胡昔权，等.高频重复经颅磁刺激对脑卒中后认知功能障碍的影响[J].中国康复医学杂志，2018， 33（7）：763-769.
[3] Aben HP，Biessels GJ，Weaver NA，et al. Extent to which network hubs are affected by ischemic stroke predicts cognitive recovery [J]. Stroke，2019，50（10）：2768-2774.
[4] Wang C，Li F，Guan Y，et al. Bone marrow stromal cells combined with oxiracetam influences the expression of B-cell lymphoma 2 in rats with ischemic stroke [J]. J Stroke Cerebrovasc Dis，2014，23（10）：2591-2597.
[5] 王丽.天麻素片联合盐酸帕罗西汀对老年脑卒中后焦虑抑郁患者血清BDNF、IGF-1浓度的影响[J].中国老年学杂志，2017，37（21）：5403-5405.
[6] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[7] 中华医学会神经病学分会痴呆与认知障碍学组写作组.血管性认知障碍诊治指南[J].中华神经科杂志，2011，44（2）：142-147.
[8] 周华，高炳忠，邱晨红，等.蒙特利尔认知评估量表在血管性认知功能障碍中的应用[J].临床神经病学杂志，2010， 23（3）：221-223.
[9] 汤加利，史惟，郭金颖，等.学龄期脑瘫患儿日常生活活动能力状况及影响因素分析[J].中国康复医学杂志，2014， 29（6）：552-556.
[10] 段睿康，付剑亮.脑卒中后认知功能障碍[J].中国老年学杂志，2017，37（24）：6272-6274.
[11] Mehta A，Mahale R，Buddaraju K，et al. Efficacy of neuroprotective drugs in acute ischemic stroke：is it helpful? [J]. J Neurosci Rural Pract，2019，10（4）：576-581.
[12] Guo DX，Zhu ZB，Zhong CK，et al. Serum cystatin C levels are negatively correlated with post-stroke cognitive dysfunction [J]. Neural Regen Res，2020，15（5）：922-928.
[13] 王瑞云，于宏丽，赵继巍，等.脑卒中后认知功能障碍的研究进展[J].中华神经医学杂志，2017，16（11）：1129-1133.
[14] 赵建国.急性脑梗死患者血管性认知功能障碍的影响因素分析[J].河北医学，2018，24（5）：841-844.
[15] Liu J，Zheng L，Cheng Y，et al. Trends in outcomes of patients with ischemic stroke treated between 2002 and 2016：insights from a Chinese cohort [J]. Circ Cardiovasc Qual Outcomes，2019，12（12）：e005610.
[16] 李坤彬，姚先丽，孙平鸽，等.奥拉西坦注射液联合康复训练治疗脑卒中后血管性认知障碍的临床疗效[J].中国老年学杂志，2015，35（10）：2698-2700.
[17] 艾艳萍，丁涛，蔡桃英，等.天麻素对急性缺血性脑卒中后痴呆患者的疗效分析[J].西南国防医药，2018，28（11）：1048-1051.
[18] Wang J，Sun R，Li Z，et al. Combined bone marrow stromal cells and oxiracetam treatments ameliorates acute cerebral ischemia/reperfusion injury through TRPC6 [J]. Acta Biochim Biophys Sin （Shanghai），2019，51（8）：767-777.
[19] 李小燕.奥拉西坦治疗缺血性脑卒中后认知功能障碍的临床观察[J].中国医院用药评价与分析，2014，18（10）：884-887.
[20] 陈奕奕，刘颖璇，杨伟超.奥拉西坦辅助治疗脑白质病并认知功能障碍的效果及安全性观察[J].中国医药科学，2018，8（24）：69-71，114.
[21] 何珊珊，李锐，吴迪，等.天麻素对脑缺血再灌注小鼠海马新生神经元的保护作用[J].现代生物医学进展，2015， 15（32）：6241-6244，6311.
[22] 孙奎亮，杨凡喜，王军，等.脑卒中的炎症免疫机制研究进展[J].中国老年学杂志，2015，35（18）：5360-5362.
[23] 邓石雄.和肽素和降钙素原及其他炎症指标在脑卒中患者发生感染中的预测价值[J].中国老年学杂志，2014， 34（8）：2048-2050.
[24] 赵磊，王润润.天麻素注射液治疗脑卒中后抑郁症的临床分析[J].中国实用神经疾病杂志，2013，16（1）：62-63. |
|
|
|
